东宝生物
(300239)
| 流通市值：31.31亿 | | | 总市值：31.52亿 |
| 流通股本：5.90亿 | | | 总股本：5.94亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 633,112,065.92 | 444,275,439.67 | 241,778,598.22 | 974,512,217.68 |
| 营业收入 | 633,112,065.92 | 444,275,439.67 | 241,778,598.22 | 974,512,217.68 |
| 二、营业总成本 | 555,269,833.32 | 383,990,220.35 | 209,838,876.06 | 834,255,884.59 |
| 营业成本 | 489,880,095.68 | 343,596,466.41 | 191,383,244.9 | 725,695,459.9 |
| 税金及附加 | 6,864,108.18 | 4,788,685.67 | 2,479,134.28 | 12,578,092.49 |
| 销售费用 | 12,635,523.41 | 7,985,769.47 | 3,627,263.9 | 19,612,333.51 |
| 管理费用 | 33,584,181.69 | 21,357,197.04 | 10,003,077.61 | 51,522,312.4 |
| 研发费用 | 16,012,452.92 | 8,976,532.89 | 4,046,567.55 | 26,100,645.39 |
| 财务费用 | -3,706,528.56 | -2,714,431.13 | -1,700,412.18 | -1,252,959.1 |
| 其中:利息费用 | 1,959,679.91 | 1,284,510.01 | 631,693.86 | 5,140,212.77 |
| 其中:利息收入 | 5,517,789.65 | 3,557,296.32 | 2,180,638.86 | 6,367,697.87 |
| 加:投资收益 | -3,007,719.11 | -2,215,682.57 | -1,158,672.48 | -4,329,558.16 |
| 资产处置收益 | -277,943.39 | -278,808.13 | -279,378.71 | 76,746.62 |
| 资产减值损失(新) | -1,548,347.56 | -394,495.25 | 135,514.67 | -1,448,662.74 |
| 信用减值损失(新) | 552,636.23 | 385,153.47 | 62,020.94 | -1,556,406.64 |
| 其他收益 | 9,035,682.43 | 6,657,354.64 | 2,868,307.89 | 10,880,743.05 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 82,596,541.2 | 64,438,741.48 | 33,567,514.47 | 143,879,195.22 |
| 加:营业外收入 | 116,706.7 | 109,906.65 | 33,136 | 1,619,462.04 |
| 减:营业外支出 | 890,452.41 | 883,312.66 | 875,742.61 | 1,006,068.53 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 81,822,795.49 | 63,665,335.47 | 32,724,907.86 | 144,492,588.73 |
| 减:所得税费用 | 10,287,606.93 | 8,224,065.18 | 4,643,140.22 | 17,121,471.22 |
| 六、净利润 | 71,535,188.56 | 55,441,270.29 | 28,081,767.64 | 127,371,117.51 |
| 持续经营净利润 | 71,535,188.56 | 55,441,270.29 | 28,081,767.64 | 127,371,117.51 |
| 归属于母公司股东的净利润 | 66,273,700.7 | 51,341,802.92 | 25,961,526.88 | 119,885,372.42 |
| 少数股东损益 | 5,261,487.86 | 4,099,467.37 | 2,120,240.76 | 7,485,745.09 |
| (一)基本每股收益 | 0.11 | 0.09 | 0.04 | 0.2 |
| (二)稀释每股收益 | 0.1 | 0.08 | 0.04 | 0.2 |
| 九、综合收益总额 | 71,535,188.56 | 55,441,270.29 | 28,081,767.64 | 127,371,117.51 |
| 归属于母公司股东的综合收益总额 | 66,273,700.7 | 51,341,802.92 | 25,961,526.88 | 119,885,372.42 |
| 归属于少数股东的综合收益总额 | 5,261,487.86 | 4,099,467.37 | 2,120,240.76 | 7,485,745.09 |
| 公告日期 | 2024-10-28 | 2024-08-28 | 2024-04-24 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |